Sign in

NCT06322992Completed

App-Assisted Day Reconstruction to Reduce Treatment Burden and Logistic Toxicity in Cancer Patients - Aim 3

Source: ClinicalTrials.gov · Last updated 5 Feb 2025

Brief summary (registry, in English)

The goal of this observational study is to develop a mobile app for cancer patients undergoing treatments. In Aim 3, patients will rate the quality of the app using the Mobile App Rating Scale (MARS) and their satisfaction with the three key app features. The outcome of this project will be a final prototype app with 70% of patients indicating an overall MARS score of 4.0 or more and satisfaction with the three features.

Status (registry)
Completed
Study type
Observational
Enrollment
62 (actual)
First submitted
13 Mar 2024
Start date
14 May 2024
Primary completion date
20 Oct 2024
Lead sponsor
Daynamica, Inc.
NCT number
NCT06322992

What you commit to

  • Study type: Observational
  • Participants enrolled: 62
  • From 14 May 2024 to the primary completion date, 20 Oct 2024
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • NA

Who the study is looking for

  • cancer patients undergoing treatments

Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Masonic Cancer Center
Coordinator of this site? Confirm its status
MinneapolisUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.